Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy

Introduction: Multiple immune checkpoint inhibitors (ICIs) that modulate immune cells in the periphery and the tumor microenvironment (TME) have been approved, as have the therapeutic cancer vaccines sipuleucel-T for metastatic castration-resistant prostate cancer and talimogene laherparepvec (T-VEC...

Full description

Bibliographic Details
Main Authors: Julie M. Collins, Jason M. Redman, James L. Gulley
Format: Article
Language:English
Published: Taylor & Francis Group 2018-08-01
Series:Expert Review of Vaccines
Subjects:
Online Access:http://dx.doi.org/10.1080/14760584.2018.1506332